Ekso Bionics Hlds

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN RAFAEL, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York on September 11-13, 2023.

Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2023 Results Conference Call July 27, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Hello, and welcome to the Ekso Bionics Q2 2023 Financial Results Conference Call and Webcast [Operator Instructions].

Ekso Bionics Holdings, Inc. (EKSO) Q2 2023 Earnings Call Transcript

Ekso Bionics (EKSO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.23 per share a year ago.

Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates

SAN RAFAEL, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report Second Quarter 2023 Financial Results on July 27, 2023

Ekso Bionics Holdings, Inc. (EKSO) Q1 2023 Earnings Call Transcript.

Ekso Bionics Holdings, Inc. (EKSO) Q1 2023 Earnings Call Transcript

Highest Quarterly Revenues in Company History SAN RAFAEL, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2023.

Ekso Bionics Announces 61% Increase in First Quarter 2023 Revenues

SAN RAFAEL, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2023 after the close of trading on Thursday, April 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report First Quarter 2023 Financial Results on April 27, 2023

- SoldierStrong to Donate Device to the Charlie Norwood Department of Veteran Affairs Medical Center in Augusta, GA - SAN RAFAEL, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that SoldierStrong, a non-profit organization dedicated to improving Veterans' lives through innovative technology, has purchased an Ekso Indego Therapy device that it will donate to the Spinal Cord Injury Unit at Charlie Norwood VA Medical Center in Augusta, Georgia.

Ekso Bionics Announces Ekso Indego Therapy Order by SoldierStrong

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Fourth Quarter 2022 Financial Results Conference Call.

Ekso Bionics Holdings, Inc. (EKSO) Q4 2022 Earnings Call Transcript

SAN RAFAEL, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2022.

Ekso Bionics Reports Fourth Quarter and Year End 2022 Results

SAN RAFAEL, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced it will showcase the new Ekso Indego Therapy with Functional Electrical Stimulation (FES) at the upcoming American Physical Therapy Association's Combined Sections Meeting on February 23-25 in San Diego, California. The Company recently filed a Premarket Notification 510(k) with the U.S. Food and Drug Administration that covers the addition of integrated FES hardware and software to Ekso Indego Therapy, a lower-limb powered exoskeleton recently acquired by Ekso.

Ekso Bionics to Showcase Integrated Functional Electrical Stimulation for Indego Therapy at APTA Meeting

Broadens Ekso Bionics' product portfolio into home use

Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Steven Sherman - Chairman and Chief Executive Officer Scott Davis - President and Chief Operating Officer Jerome Wong - Chief Financial Officer Operator Greetings and welcome to Ekso Bionics Third Quarter 2022 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded.

Ekso Bionics Holdings, Inc. (EKSO) Q3 2022 Earnings Call Transcript

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -37.50% and 7.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates

Quarterly Record of 33 EksoNR Bookings in Q3 2022

Ekso Bionics Reports Third Quarter 2022 Results

SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Ekso Bionics has added a new use case for the EksoNR exoskeleton, multiple sclerosis, opening some new avenues for marginal revenue growth. Pre-Covid, Ekso had started to see sharp improvements in operating margins, but that trend came to a clear stop over the last two years.

Ekso Bionics: Fragile Opportunity

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2022 Results Conference Call July 28, 2022 4:30 PM ET Company Participants David Carey - Head, Investor Relations Steven Sherman - Chairman & CEO Scott Davis - President & Chief Operating Officer Jerome Wong - interim Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Kyle Bauser - LakeStreet Capital Operator Hello, and welcome to the Ekso Bionics Q2 2022 Financial Results Conference Call.

Ekso Bionics Holdings, Inc. (EKSO) CEO Steven Sherman on Q2 2022 Results - Earnings Call Transcript

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

RICHMOND, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2022.

Ekso Bionics Reports Second Quarter 2022 Results

RICHMOND, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2022 after the close of trading on Thursday, July 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report Second Quarter 2022 Financial Results on July 28

First FDA Cleared Exoskeleton for Rehabilitation Use in Patients with Multiple Sclerosis

Ekso Bionics Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Multiple Sclerosis Patients

RICHMOND, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Jerome Wong as Interim Chief Financial Officer following the departure of current CFO Jack Glenn. Mr. Glenn resigned effective June 17, 2022 to pursue a new position at another public company. Mr. Glenn's resignation is not the result of any dispute or disagreement with the Company including any matters relating to the Company's accounting practices or financial reporting.

Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer

Ekso Bionics (EKSO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Ekso Bionics (EKSO) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 12.20% and 19.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Ekso Bionics Hlds Stock (EKSO)